ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

REDX Redx Pharma Plc

18.50
-0.25 (-1.33%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Redx Pharma Plc LSE:REDX London Ordinary Share GB00BSNB6S51 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.25 -1.33% 18.50 18.00 19.00 18.75 18.50 18.75 62,901 08:26:56
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 4.2M -33.16M -0.0852 -2.17 71.96M
Redx Pharma Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker REDX. The last closing price for Redx Pharma was 18.75p. Over the last year, Redx Pharma shares have traded in a share price range of 17.50p to 36.00p.

Redx Pharma currently has 388,985,916 shares in issue. The market capitalisation of Redx Pharma is £71.96 million. Redx Pharma has a price to earnings ratio (PE ratio) of -2.17.

Redx Pharma Share Discussion Threads

Showing 676 to 697 of 700 messages
Chat Pages: 28  27  26  25  24  23  22  21  20  19  18  17  Older
DateSubjectAuthorDiscuss
26/3/2024
18:44
If you read through the Jazz results it mentions the Redx Pharma deals under heading Business Updates/Corporate Development

........."KRAS Inhibitor Program Agreement:

In February 2024, the Company acquired Redx Pharma's KRAS inhibitor program, which includes G12D selective and pan-KRAS molecules, further expanding Jazz's early-stage oncology pipeline.".......

muchodinero
26/3/2024
15:50
Thanks for that, good news indeed.
bermudashorts
26/3/2024
15:39
Jazz Pharma post record sales for 2023 including over $1 billion 4th Qtr sales for first time. Great set of results for Jazz Pharma and includes mention of buying rights to Redx Kras inhibitor in the results. A great global Pharma partner for Redx it appears and potential $870 million in milestone and future royalty payments in the future. Also payments to Redx for future development work on KRAS programme as well it seems? GLA Adyor!
muchodinero
18/3/2024
12:01
Big rise coming,NT to buy as so little stock about, plenty of large buys this morning,MM's will have to let it go, eventually.
bri15
15/2/2024
07:21
paulscb

Redx have another $15m in potential near term milestones from the previous deals with Jazz and AstraZeneca.

bermudashorts
13/2/2024
12:55
Looks like someone is hoovering up a few shares 🤔 I think the Polar Capital sale last week softened the share price for a few days?
muchodinero
07/2/2024
19:56
is there a telegram group? link ? Thanks
everready1
07/2/2024
19:49
Do people pay you in a telegram group for this research you do? Seriously?LOL
paulscb
07/2/2024
19:44
You may want to go study the 16 month gap between Jazz initial agreement and subsequent milestone payments on a different agreement here.
paulscb
07/2/2024
18:04
And you know when the milestones are coming ? What they are? How much per milestone? This is the first of the promised news run this year. More to come.
babbler
07/2/2024
15:10
What's your point. You should see the major investment list here then you might sell APH for this. ;)
babbler
07/2/2024
14:48
https://www.alliancepharmaceuticals.com/investors/shareholder-centre/significant-shareholders/
blackhorse23
07/2/2024
09:55
Largest volume in over 3 years
olly353
07/2/2024
09:25
Great news today.The KRAS inhibitor program was peripheral to the main pipeline so a real bonus. That must extend cash out to the end of 2024. And give a potential milestone pipeline of some $1.5 billion in total. Two value inflection points over the next six months will be important in respect of ROCK inhibitor p2a in Fibrosis and porcupine p2 cancer candidate. The extended cash runway will not put them under pressure when partnering the latter if results are good.

Could this be the catalyst for a rerate. I think the recent trinity report had a target of 90p ??

pdt
07/2/2024
08:38
Give it up mate. Spamming all the boards daily with APH. No one cares.
babbler
07/2/2024
08:18
Money moving to APH
blackhorse23
08/3/2023
08:52
Beware,Beware, Beware all small pharma
Alack and alas many have trod this way to Hades before
Their souls litter the path..
Follow them not…

volsung
23/2/2023
09:18
umm. terms seem unfair to REDX
pejaten
04/9/2022
13:59
Put RXC004 into your search Engine then refer to my last post.

It gives real hope for specialist cancer and fibrosis treatment of previously extremly hard to treat tumours.

.....and potentially will give you the opportunity to buy into RedX before the news is widely available as to just who is responsible for this potential life-saving research.

knitcraft
04/9/2022
13:37
The following news item was first published in The "I" last week and has been subsequently picked up by other publications and TV news. The link below is to an ITV news item.

The intriguing and very important information that is missing from all the items, is the name of the company doing the research on RXC004.

It happens to be RedX and when that fact becomes widely known I would expect a reassessment of the value of RedX.

In June Trinity Delta,a reputable research company specialising in biomedicals, valued RedX shares on an undiluted basis at £1.38. The share price is currently 60p. Redx has at least 4 very promising research streams on the go.

From the research note in June 2022
Redx Pharma continues to deliver, with H122 results highlighting broad progress across the pipeline. The lead assets, RXC004, a porcupine inhibitor for oncology, and RXC007, a ROCK2 inhibitor for fibrosis, are advancing through Phase II and Phase I trials respectively, with further value inflection expected during 2022-23. Milestone receipts from AstraZeneca and Jazz Pharmaceuticals are tangible evidence of further progress with partnered programmes. Selection of RXC008, a GI targeted ROCK inhibitor as the next development candidate demonstrates earlier stage development is similarly bearing fruit. Our new rNPV-based valuation, updated to reflect H122 results and the May £34.3m (gross) equity raise, is £458m (vs £434m), or 138p/share.

It is worth looking at the company in more detail to fully appreciate what they are about. Look at the highly qualified team that has been assembled. Also check the lines of research they are pursuing and the major pharmaceutical companies they are associated with.
Also have look at the major shareholders involved.

Now look at this. Very few know this is about RedX. I suspect they soon will!

knitcraft
11/1/2022
11:00
Looking ready for a breakout on the up side.
knitcraft
23/12/2021
07:39
Another great Milestone payment RNS. Well done REDX and Merry Christmas all holders.
wapper
Chat Pages: 28  27  26  25  24  23  22  21  20  19  18  17  Older

Your Recent History

Delayed Upgrade Clock